The Sarah Cannon Research Institute is looking for participants for a clinical trial of the drug Ixempra, which has shown promise as a treatment for triple-negative breast cancer in previous trials. According to the Memphis Commercial Appeal, women with triple-negative who are interested in participating should contact Sandra Dodd, research administrator with the Family Cancer Center, at (901) 747-9081.
The trial is part of a nationwide trial sponsored by Bristol-Myers Squibb, maker of Ixempra. The study will continue through 2011.
No comments:
Post a Comment